Sage Advises Solasia on a Global Partnership for Darinaparsin, a Novel Treatment for Peripheral T Ce
Solasia has engaged The Sage Group to manage a program to establish a global partnership regarding licensing of its Darinaparsin product in USA and Europe. Darinaparsin or SP-02 is a new product from Solasia for the treatment of Peripheral T-Cell Lymphoma (PTCL). Solasia is working with Sage Group to license SP-02 in USA and Europe where they own all rights. Solasia Pharma (“Solasia” or the “Company”; www.solasia.co.jp) is a privately owned company based in Japan. It is headquartered in Tokyo, with a subsidiary in Shanghai and offices in Beijing. Solasia has a strong and experienced management team from Amgen, Searle, Roche, Takeda and Sosei. Solasia is a specialty pharmaceutical company est